Alteplase
- Generic Name
- Alteplase
- Brand Names
- Activase, Cathflo, Cathflo Activase
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 105857-23-6
- Unique Ingredient Identifier
- 1RXS4UE564
- Background
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...
- Indication
Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...
- Associated Conditions
- Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
- Associated Therapies
- -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- University of Windsor
- Target Recruit Count
- 150
- Registration Number
- NCT02225782
- Locations
- 🇨🇦
Windsor Regional Hospital, Windsor, Ontario, Canada
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT02182011
Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Reza Behrouz, DO
- Registration Number
- NCT02180204
- Locations
- 🇺🇸
The Ohio State University College of Medicine, Columbus, Ohio, United States
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 313
- Registration Number
- NCT02072226
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01958164
- Locations
- 🇷🇺
135.323.3 Boehringer Ingelheim Investigational Site, Krasnoyarsk, Russian Federation
🇷🇺135.323.1 Boehringer Ingelheim Investigational Site, Akhangelsk, Russian Federation
🇷🇺135.323.2 Boehringer Ingelheim Investigational Site, Krasnodar, Russian Federation
Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Lars Thomassen
- Target Recruit Count
- 1050
- Registration Number
- NCT01949948
- Locations
- 🇳🇴
Molde Hospital, Molde, Norway
🇳🇴Haugesund Hospital, Haugesund, Norway
🇳🇴Baerum Hospital, Rud, Norway
EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 344
- Registration Number
- NCT01930682
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Rush University Medical Center
- Registration Number
- NCT01878136
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
- Conditions
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 55
- Registration Number
- NCT01835067
- Locations
- 🇬🇧
Hull & East Yorkshire Hospital NHS Trust, Hull, United Kingdom
🇬🇧King's College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧Southend University Hospital NHS Foundation Trust, Southend, United Kingdom
Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 499
- Registration Number
- NCT01827046
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.